An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment

Volchegorskii I.A.; Izarovskii B.V.; Shamaeva T.N.; Izarovskaia I.V.

doi:https://doi.org/10.17116/jnevro202112109163

Volchegorskii I.A.

South Ural State Medical University

Izarovskii B.V.

Chelyabinsk Regional Clinical Narcology Hospital

Shamaeva T.N.

South Ural State Medical University

Izarovskaia I.V.

South Ural State University

An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment

Authors:

Volchegorskii I.A., Izarovskii B.V., Shamaeva T.N., Izarovskaia I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9): 63‑71

DOI: 10.17116/jnevro202112109163

Read: 2853 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Volchegorskii IA, Izarovskii BV, Shamaeva TN, Izarovskaia IV. An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):63‑71. (In Russ.)
https://doi.org/10.17116/jnevro202112109163

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To compare the effect of 3-oxypyridine and succinic acid derivatives (emoxypine, reamberin, mexidol) on the time of reduction of anxiety and depression symptoms in the standard treatment of alcohol withdrawal syndrome (AWS).

MATERIAL AND METHODS

A short-term prospective placebo-controlled double blind randomized study of the effect of emoxypine, reamberin, mexidol on the dynamics of reduction of anxiety and depression clinical symptoms in the course of a 14-day day hospital treatment of AWS was conducted. The severity of anxiety symptoms was assessed on a daily basis by using the Hamilton Anxiety Rating Scale (HARS). Symptoms of depression were assessed with the Montgomery-Asberg Depression Rating Scale (MADRS). Reduction of certain objective anxiety and depression symptoms was noticed at 0 point of the corresponding HARS and MADRS items. On the 1^st and 14^th day of treatment, the Zung Self-Rating Anxiety Scale (ZSRAS) and the Beck Depression Inventory (BDI) were additionally used.

RESULTS AND CONCLUSION

All the studied drugs reduced the duration of certain anxiety and depression symptoms during AWS treatment. The degree of this effect depended on the features of the chemical structure of a drug. Mexidol accelerated the reduction of «dread», «respiratory» and «cardiovascular» anxiety symptoms (HARS) by 25—50%. «Reduced appetite» and «concentration difficulty» (MADRS) improved by 28.5%. Reamberin reduced the duration of «gastrointestinal» and «respiratory» anxiety symptoms (HARS) by 17—50% and «inner tension» (MADRS) by 7%. Emoxypine accelerated the reduction of «insomnia» and «respiratory» symptoms (HARS) but did not affect the duration of objective depression symptoms (MADRS). Emoxypine and reamberin reduced the severity of affective and cognitive symptoms (BDI) by 32—37%. None of the drugs affected self-reported anxiety (ZSRAS). The most balanced treatment of depressive symptoms was provided by reamberin, which was the only of the studied drugs that simultaneously reduced both the duration of objective symptoms and the severity of subjective disorders of affective status in alcohol withdrawal.

Keywords:

alcohol withdrawal

anxiety

depression

3-oxypyridine and succinic acid derivatives

Authors:

Volchegorskii I.A.

South Ural State Medical University

Izarovskii B.V.

Chelyabinsk Regional Clinical Narcology Hospital

Shamaeva T.N.

South Ural State Medical University

Izarovskaia I.V.

South Ural State University

Received:

22.12.2020

Accepted:

28.12.2020

Close metadata

References:

Ivanets NN, Lavrinenko OV, Maximova TN. Clinical features of depressive disorders complicated by alcohol abuse. Socialnaya i Klinicheskaya Psihiatriya. 2016;26(2):55-59. (In Russ.).
Andryuschenko AV, Shulyak YA. Alcohol addiction and depression: approaches to diagnostics and therapy. Medicinskii Sovet. 2016;19:28-36. (In Russ.). https://doi.org/10.21518/2079-701X-2016-19-28-36
Smith JP, Carrie L, Randall CL. Anxiety and alcohol use disorders: Comorbidity and treatment considerations. Alcohol Research. 2012;34(4):414-431.
Roshchina OV, Rozin AI, Schastnyy ED, Bokhan NA. Clinical value of comorbidity of affective disorders and alcohol dependence. Bulletin of Siberian Medicine. 2019;18(4):110-118. (In Russ.). https://doi.org/10.20538/1682-0363-2019-4-110-118
Paschall MJ, Freisthler B, Lipton RI. Moderate Alcohol Use and Depression in Young Adults: Findings From a National Longitudinal Study. American Journal of Public Health. 2005:95(3):453-457. https://doi.org/10.2105/ajph.2003.030700
Skryabin VYu, Zastrozhin MS, Brun EA, Sychev DA. Benzodiazepine tranquilizers as a «gold standard»” for the treatment of patients with alcohol withdrawal syndrome (literature review). Sovrem. Ter. Psih. Rasstrojstv. 2020;1:21-28. (In Russ.). https://doi.org/10.21265/psyph.2020.33.41.003
Schaefer TJ, Hafner JW. Are benzodiazepines effective for alcohol withdrawal? Annals of Emergency Medicine. 2013;62(1):34-35. https://doi.org/10.1016/j.annemergmed.2012.03.017
Ponizovskiy PA, Gofman AG. Depression in alcohol addicted patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;7:146-150. (In Russ.). https://doi.org/10.17116/jnevro201511571146-150
Abdallah CG, Thomas G, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. Ketamine’s Mechanism of Action: A Path to Rapid-Acting Antidepressants. Depress Anxiety. 2016;33(8):689-697. https://doi.org/10.1002/da.22501
Gosudarstvenniy reestr lekarstvennih sredstv. Accessed November 9, 2020. (In Russ.). https://grls.pharm-portal.ru/grls
Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, Bodykhov MK, Kichuk IV, Gudkova YuV, Soldatenkova TD, Kondrasheva TT, Kalinina EV, Novichkova MD, Kerbikov OB. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. Prilozhenie «Insult». 2006;18:47-54. (In Russ.).
Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.).
Volchegorskii IA, Mester KM. Effects of 3-hydroxypyridine and succinic acid derivatives on the dynamics of dorsalgia and affective disorders after surgical treatment of disc herniation. Eksp Klin Farmakol. 2010;73(1):33-39. (In Russ.).
Volchegorskii IA, Pravdin EV, Uzlova TV. Effect of 3-oxypyridine and succinic acid derivatives on affective status in recrudescence of inflammatory diseases of uterus and its appendages. Eksp Klin Farmakol. 2012;75(11):22-27. (In Russ.).
Prikaz Ministerstva zdravoohraneniya Rossiyskoy Federacii ot 04.09.12 №135n (zaregistrirovano v Minuste Rossii 19.12.12 №26193) «Ob utverzhdenii standarta specializirovannoy medicinskoy pomoshchi pri absinentnom sostoyanii, vizvannom upotrebleniem psihoaktivnih veshchestv». Accessed November, 26, 2020. (In Russ.). https://ivo.garant.ru/#/document/70288222/paragraph/1:0
Agibalova TV, Altshuler VB, Vinnikova MA, Kozireva AV, Kravchenko SL, Lobacheva AS, Nenasteva AU, Petuhov AE, Titkov MS, Utkin SI. Psihiatricheskie i povedencheskie rasstroystva, vizvannie upotrebleniem alkogolya. Sindrom otmeni alkogolya (alkogolnoe absinentnoe sostoyanie): klinicheskie rekomendacii. 2017. Accessed November, 26, 2020. (In Russ.). https://r-n-l.ru/actualdoc/2018/kp2018/kp_sindrom_otm_alkoholya2018upd.pdf
Dvoirin VV, Klimenkov AA. Metodika kontroliruemih klinicheskih ispitaniy. M.: Medicina; 1985. (In Russ.).
Avedisova AS, Chahava VO, Lupaeva NV. Placebo-effekt v psihiatrii (obzor literaturi). Rossiyskiy Psihiatricheskiy Zhurnal. 2003;3:65-71. (In Russ.).
Belova AN. Shkali, testi i oprosniki v nevrologii I neyrohirurgii. 3-e izd. pererab. i dop. M.: Prakticheskaya medicina; 2018. (In Russ.).
Linke SE, Rutledge T, Johnson BD, Vaccarino V, Bittner V, Cornell CE, Eteiba W, Sheps DS, Krantz DS, Parashar S, Merz CNB. Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: A report from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Arch Gen Psychiatry. 2009;66(5):499-507. https://doi.org/10.1001/archgenpsychiatry.2009.27
Lustman PJ, Clouse RE, Griffith LS, Carney RM, Freedland KE. Screening for depression in diabetes using the beck depression inventory. Psychosomatic Medicine. 1997;59:24-31.
Sekunda UI, Shprah VV, Vasilev UN. Klinicheskie prediktori effektivnosti monoterapii escitalopramom panicheskogo rasstroystva. Sibirskiy Medicinskiy Zhurnal. 2006;8:24-26. (In Russ.).
Kremec KG. Carbamazepine for treatment of alcohol withdrawal. International Neurological Journal. 2012;48(2):163-166. (In Russ.).
Shcherbakova IV, Krylatykh VYu, Bardenshteyn LM. The psycho-pharmacotherapy of anxiety disorders: problem actual view. Rossiiskii meditsinskii zhurnal (Medical Journal of the Russian Federation, Russian Journal). 2017;23(2):107-112. (In Russ.). https://doi.org/10.18821/0869-2106-2017-23-2-107-112
Volchegorskii IA, Izarovskii BV, Shamaeva TN. The effect of 3-oxypyridine and succinic acid derivatives on the dynamics of clinical manifestations of alcohol withdrawal syndrome (AWS) in course of standard treatment. Voprosy Narkologii. 2020;191(8):24-47. (In Russ.). https://doi.org/10.47877/0234-0623_2020_08_24
Novik AA, Ionova TI, Kaljadina SA, Kishtovich AV. Symptom assessment in patients with hematological malignancies: discrepancies in estimation of symptom severity and symptom management efficacy between a patient and a physician. Klinicheskaja Onkogematologija. 2008;1(3):238-245. (In Russ.).